SWP
SUPN icon

Stratos Wealth Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Stratos Wealth Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-227
Closed -$11K – 2301
2018
Q3 		$11K Buy
+227
New +$11.2K ﹤0.01% 2155
2018
Q2 		– Sell
-246
Closed -$11K – 2383
2018
Q1 		$11K Sell
246
-40
-14% -$1.67K ﹤0.01% 2286
2017
Q4 		$11K Buy
+286
New +$11.3K ﹤0.01% 2133

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Stratos Wealth Partners's SUPN Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 227 shares — an estimated $11K sold.

Stratos Wealth Partners first reported a position in SUPN in Q4 2017 and held it in 3 quarters. The position peaked at $11K in Q3 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 227 Supernus Pharmaceuticals shares in Q4 2018, an estimated $11K.
  • Stratos Wealth Partners first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Stratos Wealth Partners's Supernus Pharmaceuticals position peaked at $11K in Q3 2018.
  • 274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.